BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
MARÍA DOLORES
SANTOS BUELGA
Investigadora Predoctoral
Publicaciones en las que colabora con MARÍA DOLORES SANTOS BUELGA (33)
2022
-
Aportación de la farmacocinética al tratamiento con fenobarbital: aplicación a algunos casos clínicos
Farmajournal, Vol. 7, Núm. 1, pp. 83-91
-
Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients
Pharmaceutics, Vol. 14, Núm. 4
2020
-
Farmacocinética poblacional de fenitoína en pacientes adultos
Farmajournal, Vol. 5, Núm. 2, pp. 15-26
-
Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy
European Journal of Pharmaceutical Sciences, Vol. 153
2018
-
Age as a Factor of Differentiation in Predictive Models of Valproic Acid Pharmacokinetics
1st Global Congress of Pharmacy Faculties. Innovation in Pharmacy: Advances and Perspectives. September 24-28th, Salamanca, Spain 2018
-
Predicción “in silico” de la absorción de fármacos en pacientes celiacos
Farmajournal, Vol. 3, Núm. 1, pp. 87-97
2017
-
Modelos “in silico” para la predicción de la absorción de fármacos administrados por vía oral (SIMCYP®): estatinas
Farmajournal, Vol. 2, Núm. 2, pp. 69-79
2016
-
Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma
British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527
2014
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2011
-
Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
2009
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis
Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280
2008
-
Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy
Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489
2006
-
Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia
Clinical Pharmacokinetics, Vol. 45, Núm. 12, pp. 1227-1238
2005
-
Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies
Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941
-
Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies
Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941
2004
-
Iniciación de un programa de monitorización de lamotrigina en pacientes epilépticos
Atencion Farmaceutica, Vol. 6, Núm. 2, pp. 97-101
2002
-
Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations
Clinical Pharmacokinetics, Vol. 41, Núm. 2, pp. 115-135
2001
-
Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy
Clinical Pharmacokinetics, Vol. 40, Núm. 1, pp. 63-71
-
Population kinetics of tobramycin in neonates
Therapeutic Drug Monitoring, Vol. 23, Núm. 3, pp. 202-208